Q32 Bio Inc QTTB.O:
Q32 BIO INC: TO DISCONTINUE RENAL BASKET TRIAL FOR ADX-097 TO CONSERVE RESOURCES
Q32 BIO INC: EVALUATE STRATEGIC OPTIONS FOR ITS TISSUE-TARGETED COMPLEMENT INHIBITOR PLATFORM
Q32 BIO INC: CASH RUNWAY EXPECTED TO EXTEND TO 2H'26
Q32 BIO INC: INITIATING OPEN-LABEL EXTENSION FROM SIGNAL-AA PART A IN 1H'25
Q32 BIO INC: SIGNAL-AA PART B REMAINS ON TRACK FOR INITIATION OF DOSING IN 1H'25, WITH TOPLINE DATA EXPECTED IN 1H'26
Source text: ID:nPn11yPfKa
Further company coverage: QTTB.O
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。